On July 5, 2024, Beijing Tsingke Biotech Co., Ltd. ("Tsingke") and the Future Health Laboratory of the Yangtze River Delta Innovation Center of Zhejiang University ("ZJU Innovation Laboratory") signed an agreement to establish a joint laboratory focused on nucleic acid drug delivery systems.This collaboration marks a significant step in Tsingke's advancement in the field of small nucleic acid drug delivery and signals deeper cooperation between the two entities in biopharmaceutical innovation.
Mr. Du Jun, Vice President of Tsingke said "Tsingke has always been committed to utilizing gene synthesis technology to advance the rapid development of the industry, and this collaboration with the Innovation Laboratory of ZJU is an important step forward in our research on small nucleic acid drug delivery. We hope to jointly promote innovation and development in this field through the integration of resources and complementary advantages of both parties."
The joint laboratory aims to develop an efficient and precise small nucleic acid drug delivery system and establish a novel technology platform. The collaboration between Tsingke and the ZJU Innovation Laboratory will enhance our technological innovation capabilities and market competitiveness, while also promoting the clinical application and industrialization of small nucleic acid drugs.
This signing and unveiling ceremony is not only the beginning of the cooperation between the two parties, but also the strategic upgrade of Tsingke in the field of small nucleic acid drug delivery. In the future, Tsingke and ZJU Innovation Laboratory will work together on technological innovation and scientific research results transformation, bringing new hope for the development and application of nucleic acid drugs. Both parties believe that with the full utilization of their respective strengths, the joint laboratory will be able to achieve breakthrough results in the field of mininucleic acid drug delivery research.
